Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review

Background: The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically improved the clinical effectiveness of patients with locally advanced and/or metastatic gastrointestinal stromal tumors (GIST), and this systematic review was conducted aiming at the cost-effectiveness analysis...

Full description

Bibliographic Details
Main Authors:	Mingyang Feng, Yang Yang, Weiting Liao, Qiu Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Public Health
Subjects:	cost-effectiveness economic evaluation gastrointestinal stromal tumor systematic review TKI - tyrosine kinase inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.768765/full

Similar Items

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Maria Antonietta Barbieri, et al.
Published: (2023-03-01)

Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report
by: Haidong Zhang, et al.
Published: (2023-02-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Case report of rhabdomyosarcomatous transformation of a primary gastrointestinal stromal tumor (GIST)
by: Li Li, et al.
Published: (2019-09-01)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
by: Weili Yang, et al.
Published: (2023-05-01)

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
by: Xuechao Liu, et al.
Published: (2019-10-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
by: Yu Yao, et al.
Published: (2023-01-01)

Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
by: Ji Hyun Lee, et al.
Published: (2022-05-01)

Simultaneous renal clear cell carcinoma and gastrointestinal stromal tumor in one case
by: Jin Wen, et al.
Published: (2013-01-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Gastrointestinal Stromal Tumours: A Review on Genetics, Pathology, Risk Stratification, Clinical Characteristics, Investigation, and Treatment
by: Md Tanveer Adil, et al.
Published: (2016-11-01)

GASTROINTESTINAL STROMAL TUMOR (GIST)
by: Luigi eTornillo
Published: (2014-11-01)

Bone Metastases of Gastrointestinal Stromal Tumor: A Review of Published Literature
by: Yang J, et al.
Published: (2020-02-01)

Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients
by: Monika Dudzisz-Śledź, et al.
Published: (2022-06-01)

Primary cutaneous amelanotic melanoma and gastrointestinal stromal tumor in synchronous evolution
by: Fernanda Teixeira Ortega, et al.
Published: (2017-10-01)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
by: Víctor Albarrán, et al.
Published: (2022-11-01)

Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017
by: Tiffany Patterson, et al.
Published: (2022-03-01)

Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review
by: Liu P, et al.
Published: (2020-08-01)

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key
by: Quentin Dominique Thomas, et al.
Published: (2023-03-01)

Multimodal Treatment of a Canine Lingual Melanoma Using a Combination of Immunotherapy and a Tyrosine Kinase Inhibitors
by: Alexander Berry, et al.
Published: (2022-01-01)

The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature
by: Abdallah Alzoubi, et al.
Published: (2024-01-01)

Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
by: Inoue Takaaki, et al.
Published: (2012-08-01)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
by: Sergei Boichuk, et al.
Published: (2017-12-01)

Gastrointestinal Stromal Tumor of the Tongue
by: Andrie Jeremy Formanez, et al.
Published: (2013-06-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

Precision Oncology in Gastrointestinal Stromal Tumors
by: Hiba Mechahougui, et al.
Published: (2023-04-01)

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
by: Deborah van de Wal, et al.
Published: (2022-04-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update
by: Zhaolun Cai, et al.
Published: (2021-12-01)

Broad ligament Extraintestinal Gastrointestinal Stromal Tumor (EGIST): Case report and brief overview of EGIST
by: Farr R. Nezhat, et al.
Published: (2020-08-01)

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
by: Fangrui Xiu, et al.
Published: (2023-01-01)

Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study
by: Dao-peng Yang, et al.
Published: (2020-01-01)

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
by: Alessandro Rizzo, et al.
Published: (2021-02-01)

A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management
by: Mohammad Nawaf AlShatnawi, et al.
Published: (2022-12-01)

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
by: Sahrun Sahrun, et al.
Published: (2019-10-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
by: Le Qiu, et al.
Published: (2014-07-01)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Prahathishree Mohanavelu, et al.
Published: (2021-04-01)

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
by: Ryo Katsumata, et al.
Published: (2023-02-01)

Deducing the Conformational Properties of a Tyrosine Kinase Inhibitor in Solution by Optical Spectroscopy and Computational Chemistry
by: Md. Lutful Kabir, et al.
Published: (2020-07-01)